Therapeutic indications

Over the past decade, advances in innovative medicines have significantly improved the treatment landscape across a range of diseases. Despite this progress, many therapeutic indications still lack effective and accessible treatment options. Technophage is committed to addressing these unmet needs through the development of novel, science-driven solutions.

The company’s pipeline is built on a set of complementary technological platforms that enable the discovery and development of differentiated therapeutic candidates across multiple indications. These include bacteriophage-based approaches, biologics such as recombinant single-domain antibodies, and drug repositioning strategies supported by in vivo model systems.

In addition to therapeutic candidates, Technophage also develops non-therapeutic products that support and enhance its overall mission. These solutions contribute to advancing research, improving development processes, and enabling broader application of the company’s technologies. Through these integrated approaches, Technophage is able to generate targeted solutions tailored to specific disease mechanisms and patient needs. This strategy supports the advancement of programs addressing diverse therapeutic indications, while maintaining flexibility to expand into new areas as scientific opportunities emerge.

By combining innovation with platform versatility, Technophage aims to accelerate the development of impactful therapies and broaden the range of indications that can benefit from its technologies.